MC
BOLT icon

Manteio Capital’s Bolt Biotherapeutics BOLT Stock Holding History

Manteio Capital’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,318
Closed -$129K – 25
2021
Q4 		$129K Buy
+1,318
New +$250K 0.17% 211

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ESCM
Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Manteio Capital's BOLT Position: Q1 2022 in Review

Manteio Capital sold out of Bolt Biotherapeutics (BOLT) in Q1 2022, closing a stake of 1,318 shares — an estimated $129K sold.

Manteio Capital first reported a position in BOLT in Q4 2021 and held it in 1 quarter. The position peaked at $129K in Q4 2021. 65 funds tracked by Wall St. Rank hold BOLT as of Q1 2022.

  • Manteio Capital reported no remaining Bolt Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Manteio Capital sold 1,318 Bolt Biotherapeutics shares in Q1 2022, an estimated $129K.
  • Manteio Capital first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 1 quarter.
  • Manteio Capital's Bolt Biotherapeutics position peaked at $129K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.